

C53-A
Vol. 30 No. 12
Replaces C53-P
Vol. 28 No. 26

Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine; Approved Guideline

This document provides information to help material manufacturers in the production and characterization of commutable reference materials, as well as to assist assay manufacturers and laboratorians in the appropriate use of these materials for calibration and trueness assessment of *in vitro* diagnostic medical devices.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



Clinical and Laboratory Standards Institute

Advancing Quality in Health Care Testing

The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the health care community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related health care issues. Our process is based on the principle that consensus is an effective and cost-effective way to improve patient testing and health care services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, we provide an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

PUBLICATIONS

A document is published as a standard, guideline, or committee report.

Standard A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

Guideline A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

Report A document that has not been subjected to consensus review and is released by the Board of Directors.

CONSENSUS PROCESS

The CLSI voluntary consensus process is a protocol establishing formal criteria for

- The authorization of a project
- The development and open review of documents
- The revision of documents in response to comments by users
- The acceptance of a document as a consensus standard or guideline

Most documents are subject to two levels of consensus—"proposed" and "approved." Depending on the need for field evaluation or data collection, documents may also be made available for review at an intermediate consensus level.

Proposed A consensus document undergoes the first stage of review by the health care community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

Approved An approved standard or guideline has achieved consensus within the health care community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (ie, that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

Our standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following CLSI's established consensus procedures. Provisions in CLSI standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are addressed by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any document. Address comments to Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

VOLUNTEER PARTICIPATION

Health care professionals in all specialties are urged to volunteer for participation in CLSI projects. Please contact us at customerservice@clsi.org or +610.688.0100 for additional information on committee participation.

C53-A

ISBN 1-56238-726-X

Volume 30 Number 12

ISSN 0273-3099

Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine; Approved Guideline

Hubert Vesper, PhD
Hendrik Emons, PhD
Matthew Gnezda, PhD
Chandra P. Jain
W. Gregory Miller, PhD
Robert Rej, PhD
Gerhard Schumann, PhD
Jill Tate, MSc
Linda Thienpont, PhD
Jeffrey E. Vaks, PhD

Abstract

Reference materials are an important requisite for ensuring reliable laboratory measurements and, thus, appropriate patient care. To ensure that a reference material is suitable for its intended purpose, its characteristics need to be assessed in a defined manner, taking all relevant aspects into consideration. This document provides information to help material manufacturers in the production and characterization of commutable reference materials, as well as assist assay manufacturers and laboratorians in the appropriate use of these materials for calibration and trueness assessment of *in vitro* diagnostic medical devices. Guidance on qualification requirements of reference materials related to the definition of the measurand, the intended use of the material, and other material specifications is provided. Information on study designs, data evaluation, and uncertainty assessment is included that is supplemental to existing guidance documents about the assessment of homogeneity, stability, and property values. This document provides a revised definition of the term *commutability* and provides guidance on how to perform commutability evaluation.

Clinical and Laboratory Standards Institute (CLSI). *Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine; Approved Guideline*. CLSI document C53-A (ISBN 1-56238-726-X). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2010.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org



Copyright ©2010 Clinical and Laboratory Standards Institute. Except as stated below, neither this publication nor any portion thereof may be adapted, copied, or otherwise reproduced, by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from Clinical and Laboratory Standards Institute ("CLSI").

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, contact the Executive Vice President, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Suggested Citation

CLSI. *Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine; Approved Guideline*. CLSI document C53-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

Proposed Guideline

September 2008

Approved Guideline

May 2010

ISBN 1-56238-726-X
ISSN 0273-3099

Committee Membership

Area Committee on Clinical Chemistry and Toxicology

David A. Armbruster, PhD,
DABCC, FACB
Chairholder
Abbott Diagnostics
Abbott Park, Illinois, USA

David G. Grenache, PhD,
MT(ASCP), DABCC
Vice-Chairholder
University of Utah, ARUP
Laboratories
Salt Lake City, Utah, USA

Yung W. Chan, MT(ASCP)
FDA Center for Devices and
Radiological Health
Rockville, MD 20993

Steven C. Kazmierczak, PhD,
DABCC, FACB
Department of Pathology
Oregon Health and Science
University
Portland, Oregon, USA

Loralie J. Langman, PhD
Mayo Clinic
Rochester, Minnesota, USA

Jeffrey E. Vaks, PhD
Roche Molecular Diagnostics
Pleasanton, California, USA

Hubert Vesper, PhD
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

Graham Henderson White, PhD
Flinders Medical Centre
Bedford Park
South Australia

Jack Zakowski, PhD, FACB
Beckman Coulter, Inc.
Brea, California, USA

Advisors

John Rex Astles, PhD, FACB
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

David M. Bunk, PhD
National Institute of Standards and
Technology
Gaithersburg, Maryland, USA

Greg Cooper, CLS, MHA
Bio-Rad Laboratories, Inc., QSD
Division
Plano, Texas, USA

Paul D'Orazio, PhD
Instrumentation Laboratory
Bedford, Massachusetts, USA

Carl C. Garber, PhD, FACB
Quest Diagnostics, Incorporated
Madison, New Jersey, USA

Uttam Garg, PhD, DABCC
Children's Mercy Hospitals and
Clinics
Kansas City, Missouri, USA

Claude Giroud, PhD
Bio-Rad Laboratories, Inc.
Marnes-La-Coquette, France

Neil Greenberg, PhD
Ortho-Clinical Diagnostics, Inc.
Rochester, New York, USA

Christopher M. Lehman, MD
University of Utah Health Sciences
Center
Salt Lake City, Utah, USA

W. Gregory Miller, PhD
Virginia Commonwealth University
Richmond, Virginia, USA

Gary L. Myers, PhD
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

David Sacks, MD
Brigham and Women's Hospital
and Harvard Medical School
Boston, Massachusetts, USA

Thomas L. Williams, MD
Nebraska Methodist Hospital
Omaha, Nebraska, US

Subcommittee on Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine

Hubert Vesper, PhD
Chairholder
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

Hendrik Emons, PhD
Institute for Reference Materials
and Measurements (IRMM)
Geel, Belgium

Matthew Gnezda, PhD
Roche Diagnostics Corporation
Indianapolis, Indiana, USA

Chandra P. Jain
Beckman Coulter, Inc.
Brea, California, USA

W. Gregory Miller, PhD
Virginia Commonwealth University
Richmond, Virginia, USA

Robert Rej, PhD
New York State Dept. of Health
Albany, New York USA

Prof. Dr. Gerhard Schumann
Institute of Clinical Chemistry
Hannover, Germany

Jillian Tate, MSc
Queensland Health Pathology
Service
Herston, Australia

Linda Thienpont, PhD
University of Ghent
Ghent, Belgium

Advisors

David M. Bunk, PhD
National Institute of Standards and
Technology
Gaithersburg, Maryland, USA

Neil Greenberg, PhD
Ortho-Clinical Diagnostics, Inc.
Rochester, New York, USA

Advisors (Continued)

Mary M. Kimberly, PhD
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

Martin H. Kroll, MD
Dallas VA Medical Center
Dallas, Texas, USA

Gary L. Myers, PhD
Centers for Disease Control and
Prevention
Atlanta, Georgia, USA

John D. Nagle, PhD, BCLD
Maine Standards Company, LLC
Windham, Maine, USA

Jeffrey E. Vaks, PhD
Roche Molecular Diagnostics
Pleasanton, California, USA

A. Milford Ward, MA, MB, BChir,
MRCS
Sheffield, United Kingdom

Staff

Clinical and Laboratory Standards
Institute
Wayne, Pennsylvania, USA

Lois M. Schmidt, DA
*Vice President, Standards
Development*

David E. Sterry, MT(ASCP)
Staff Liaison

Melissa A. Lewis, ELS
Editorial Manager

Acknowledgments

This guideline was prepared by CLSI, as part of a cooperative effort with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to work toward the advancement and dissemination of laboratory standards on a worldwide basis. CLSI gratefully acknowledges the participation of IFCC experts Prof. Dr. Gerhard Schumann, Institute of Clinical Chemistry, and Heinz G. Schimmel, PhD, Institute for Reference Materials and Measurements (IRMM), on this project.

CLSI also acknowledges the expert and his institution listed below for their contributions, advice, and help in the development of this guideline:

Dr. Zhiguo Wang
National Center for Clinical Laboratory
Beijing, People's Republic of China

Acknowledgment in Memoriam of our Subcommittee Advisor and Colleague

CLSI and the Subcommittee on Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine acknowledge the contributions of Mr. Richard R. Miller, Jr. Rick helped initiate this guideline and provided important contributions to the development of this document. His work on standardizing and harmonizing clinical laboratory measurements helped in advancing this field, and stimulated many activities and efforts that will improve laboratory measurements and thus patient care.

Contents

Abstract.....i

Committee Membership..... iii

Foreword..... vii

1 Scope..... 1

2 Introduction..... 1

3 Standard Precautions..... 4

4 Terminology..... 4

 4.1 A Note on Terminology..... 4

 4.2 Definitions 5

 4.3 Abbreviations and Acronyms 7

5 Qualification Requirements 8

 5.1 Definition of the Measurand 8

 5.2 Intended Use 8

 5.3 Material Specifications 8

6 Characterization of Homogeneity, Stability, and Property Value..... 9

 6.1 Characterization of Homogeneity 9

 6.2 Characterization of Stability 11

 6.3 Establishing Traceability 14

7 Characterization of Commutability of Reference Materials 20

 7.1 General Considerations Regarding Samples and Measurement Procedures Used
for Commutability Validation..... 20

 7.2 Logistical Considerations of a Commutability Validation 22

 7.3 Procedures for Commutability Validation and Assessing Numerical Relationships ..23

 7.4 Selection of a Procedure to Validate Commutability..... 33

 7.5 Criteria for Acceptance of the Equivalence of the Mathematical Relationship
for Native Clinical Samples and Candidate Reference Materials 34

 7.6 Reporting Commutability Information 34

8 Considerations for Reference Materials Intended for Immediate Use and/or Limited
Available Quantities..... 36

References..... 37

Appendix A. Examples of Value Transfer Procedures 40

Appendix B. Hypothetical Data Set Used for Examples of Procedures for Assessment of
Commutability 41

Appendix C. Description of a Mathematical Model Used for Evaluating Commutability of
Reference Materials Using Deming Regression 42

Appendix D. Procedure for Establishing Commutability of Reference Materials With Native
Clinical Specimens for a Pair of Measurement Methods Using Deming Regression..... 48

Contents (Continued)

Appendix E. Cross-Tables to Describe Commutability Results51

Summary of Delegate Comments and Subcommittee Responses.....52

The Quality Management System Approach.....62

Related CLSI Reference Materials63

Foreword

Appropriate patient care and effective public health activities critically depend on reliable laboratory measurements. Reliability in this context comprises ensuring accurate measurements over time across laboratories and measurement procedures. This is accomplished by evaluating and controlling the trueness and precision of measurement results and procedures. Trueness is of particular importance, because it affects the comparability of results across laboratories and measurement procedures, which is crucial for the creation and implementation of clinical guidelines and public health efforts. The definition of trueness as formulated by the International Organization for Standardization (ISO)¹ implies that true values of a measurand are established. This can be accomplished by appropriately characterized reference materials (RMs). Therefore, RMs are an important component of a reference system for ensuring reliable laboratory measurements.

A variety of ISO documents provide guidance to characterize and to assign property values to RMs. Characteristics that are important for RMs include stability, homogeneity, and commutability (ISO Guide 34,² ISO Guide 35,³ ISO 15195,⁴ ISO 15194,⁵ and ISO 17511⁶). Some of these documents are intended for a broad scientific audience dealing with a wide range of different types of measurements and, therefore, do not provide the level of detail needed for applications in laboratory medicine.

The issue of commutability is of special importance in laboratory medicine, where measuring systems are optimized to perform measurements directly in native patient samples without any prior isolation or purification of the analyte. Therefore, the assessment of trueness of the clinical measurement result needs to be ensured for measurements performed in native patient samples, and the materials used to assess trueness need to reflect the specific properties and characteristics of a native patient sample. However, the amounts of patient-derived specimen matrices such as serum, plasma, or urine from a single patient are normally not sufficient to create RMs. Therefore, specimens are pooled and otherwise altered, making them different from the usual native specimen matrices. Consequently, RMs used in laboratory medicine need to be assessed to show whether these alterations affect the measurement results in a manner that prevents the use of the RMs for assessment of trueness and assignment of values to calibrators when establishing metrological traceability.

This document provides information to assist RM manufacturers in the production and characterization of materials, and to assist users of these materials, such as test system manufacturers, external quality assessment (EQA) or proficiency testing (PT) providers, and laboratorians, to assess the applicability of a material for a specific measurement procedure or clinical application.

Key Words

Commutability, homogeneity assessment, material qualification, reference material, stability assessment

Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine; Approved Guideline

1 Scope

This guideline provides recommendations for the characterization, assessment of commutability, and assignment of analyte concentration or activity values to reference materials (RMs) that are used for calibration and trueness assessment of *in vitro* diagnostic medical devices. This includes materials such as the following:

- Certified reference materials (CRMs)
- Materials without a formal certificate but with the characteristics of a CRM and attached information sufficient for use in instrument calibration or trueness control (eg, external quality assessment [EQA] or proficiency testing [PT] materials used to assess trueness)

This guideline is not intended to be applied to materials used to assess consistency of peer groups based on target values determined from participant results in EQA/PT or interlaboratory quality control programs, control materials used for routine (field) methods, manufacturer's product-specific calibrators, or noncommutable secondary RMs.

The document integrates existing standards and guidelines with new recommendations. References to existing documents addressing certain aspects of material characterization and assignment of values are provided, and new recommendations for assessment of commutability and value transfer procedures are described.

This document provides information to assist RM manufacturers in the production and characterization of materials, and to assist users of these materials, such as test system manufacturers, EQA or PT providers, and laboratorians, to assess the applicability of a material for a specific measurement procedure or clinical application.

2 Introduction

The definition of the term *reference material* from the Council Committee on Reference Materials of ISO (ISO REMCO) states that an RM is a “material, sufficiently homogeneous and stable with reference to specified properties, which has been established to be fit for its intended use in measurement or in examination of nominal properties. **NOTE 1:** Examination of a nominal property provides a nominal property value and associated uncertainty. This uncertainty is not a measurement uncertainty. **NOTE 2:** RMs with or without assigned quantity values can be used for measurement precision control whereas only RMs with assigned quantity values can be used for calibration or measurement trueness control.”³

This CLSI guideline considers only RMs that are commutable with native clinical samples and are to be used for method calibration, to provide metrological traceability of a measurement result, or as a trueness control. Consequently, the following two subgroups of RMs are covered.

CRM³ is defined as “reference material, accompanied by documentation issued by an authoritative body and providing one or more specified property values with associated uncertainties and traceabilities, using valid procedures. **EXAMPLE:** Human serum with assigned quantity value for the concentration of cholesterol and associated measurement uncertainty stated in an accompanying certificate, used as a calibrator or measurement trueness control material.” Metrologically valid procedures for the production